The latest price target for Fennec Pharmaceuticals (NASDAQ:FENC) was reported by HC Wainwright & Co. on December 17, 2024. The analyst firm set a price target for $13.00 expecting FENC to rise to within 12 months (a possible 112.77% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Fennec Pharmaceuticals (NASDAQ:FENC) was provided by HC Wainwright & Co., and Fennec Pharmaceuticals reiterated their buy rating.

The last upgrade for Fennec Pharmaceuticals Inc happened on November 22, 2022 when Cantor Fitzgerald raised their price target to $12. Cantor Fitzgerald previously had a neutral for Fennec Pharmaceuticals Inc.

There is no last downgrade for Fennec Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fennec Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fennec Pharmaceuticals was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest Fennec Pharmaceuticals (FENC) rating was a reiterated with a price target of $13.00 to $13.00. The current price Fennec Pharmaceuticals (FENC) is trading at is $6.11, which is out of the analyst’s predicted range.